急性肺损伤中的铁和线粒之间的关系:一个小小的回顾
Yunhua Cheng1,2, Liling Zhu3, Shuangxiong Xie1,2
1The First School of Clinical Medicine of Gansu University of Chinese Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu Province, China.
PeerJ
|September 16, 2024
概括
铁和线粒是急性肺损伤 (ALI) 中的关键过程. 这项研究探讨了它们与活性氧物种 (ROS) 的联系,以及潜在的治疗点,如用于治疗ALI的mTOR和NLRP3.
科学领域:
- 关键护理医学 关键护理医学
- 细胞生物学 细胞生物学
- 病理学 病理学 病理学
背景情况:
- 急性肺损伤 (ALI) 是一种流行且致命的重症监护室疾病.
- 铁和线粒是涉及到ALI的关键病理机制.
- 铁和线粒都与活性氧物种 (ROS) 有关,但它们在ALI中的确切关系尚不清楚.
研究的目的:
- 审查和综合当前关于ALI中铁和线粒细胞衰竭的研究.
- 在ALI的背景下阐明铁和线粒之间的相互作用.
- 通过检查mTOR和NLRP3在ALI中的作用来确定潜在的治疗点.
主要方法:
- 关于铁亡,线粒和ALI的研究的文献综述.
- 分析反应性氧物种 (ROS) 在这些过程中的作用.
- 检查mTOR和NLRP3通路的参与.
主要成果:
- 铁死会加剧ALI,而线粒细胞则起着调节作用.
- ROS是铁和线粒的核心.
- 铁和线粒之间的特定调节关系需要进一步研究.
结论:
- 了解ferroptosis-mitophagy轴对于ALI的发病过程至关重要.
- mTOR和NLRP3可能代表ALI内的铁亡-线粒细胞衰变相互作用的关键调节者.
- 这项研究为开发ALI新型治疗策略提供了基础.
相关概念视频
Necrosis
4.4K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.4K
Overview of Cell Death
7.1K
Cell death is an essential process where the body gets rid of old or damaged cells. Cell proliferation and death need to be balanced, as an imbalance between the two may lead to cancer or autoimmune diseases.
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
7.1K
Acute Respiratory Failure-II
183
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
183
Translocation of Proteins into the Mitochondria
3.1K
Mitochondrial precursors are translocated to the internal subcompartments via independent mechanisms involving distinct protein machineries called translocases.
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
3.1K
Acute Respiratory Failure-V
124
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
124


